|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.300 SEK | -0.76% |
|
+2.04% | +40.69% |
| 05-22 | Intervacc AB Completes Successful Evaluation of Us Strain of Strangles Pathogen Ahead of Clinical Trials | CI |
| 05-15 | Sweden's Intervacc Elects New Chair | MT |
Company Valuation: Intervacc AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,669 | 1,313 | 479.4 | 88.61 | 314.9 | 443.1 | - | - |
| Change | - | -50.81% | -63.48% | -81.52% | 255.38% | 40.69% | - | - |
| Enterprise Value (EV) 1 | 2,553 | 1,267 | 391.2 | 54.31 | 154 | 356.1 | 347.1 | 443.1 |
| Change | - | -50.36% | -69.13% | -86.12% | 183.58% | 131.17% | -2.53% | 27.66% |
| P/E | -90.2x | -20.3x | -3.75x | -1.17x | -3.42x | -5.42x | -5.42x | -10x |
| PBR | 8.66x | 5.25x | 2.01x | 0.55x | 1x | 2.28x | 2.2x | - |
| PEG | - | -0x | -0.1x | 0x | 0x | 0.5x | - | 0.2x |
| Capitalization / Revenue | 509x | 136x | 59.8x | 7.52x | 15.7x | 27.7x | 14.8x | 2.7x |
| EV / Revenue | 487x | 131x | 48.8x | 4.61x | 7.67x | 22.3x | 11.6x | 2.7x |
| EV / EBITDA | -110x | -29.1x | -5.67x | -0.92x | -3.27x | -5.56x | -5.34x | -18.5x |
| EV / EBIT | -86.9x | -19.7x | -4.18x | -0.7x | -1.84x | -4.29x | -4.13x | -10.3x |
| EV / FCF | -53.3x | -16.7x | -8.16x | -1.01x | -2.3x | -4.81x | -4.28x | -6.82x |
| FCF Yield | -1.88% | -5.99% | -12.3% | -99.2% | -43.4% | -20.8% | -23.3% | -14.7% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.59 | -1.28 | -1.69 | -1 | -0.27 | -0.24 | -0.24 | -0.13 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 5.241 | 9.684 | 8.015 | 11.79 | 20.09 | 16 | 30 | 164 |
| EBITDA 1 | -23.24 | -43.56 | -68.98 | -58.75 | -47.09 | -64 | -65 | -24 |
| EBIT 1 | -29.39 | -64.41 | -93.58 | -77.28 | -83.5 | -83 | -84 | -43 |
| Net income 1 | -29.38 | -64.16 | -102.9 | -75.52 | -80.82 | -81.6 | -83.3 | - |
| Net Debt 1 | -115.5 | -45.52 | -88.2 | -34.3 | -160.9 | -87 | -96 | - |
| Reference price 2 | 53.200 | 26.000 | 6.330 | 1.170 | 0.924 | 1.300 | 1.300 | 1.300 |
| Nbr of stocks (in thousands) | 50,160 | 50,491 | 75,736 | 75,736 | 340,813 | 340,813 | - | - |
| Announcement Date | 18/02/22 | 17/02/23 | 16/02/24 | 13/02/25 | 17/02/26 | - | - | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.46x | 22.47x | -5.62x | - | 47.5M | |
| 33.03x | 8.6x | 25.99x | 0.06% | 56.24B | |
| 16.44x | 4.92x | 10.69x | 1.83% | 43.76B | |
| -18.06x | 4.28x | -7.47x | -.--% | 23.32B | |
| -37.29x | 12.3x | -35.89x | -.--% | 21.34B | |
| 19.43x | 3.77x | 9.8x | -.--% | 15.75B | |
| 21.69x | 4.34x | 14.37x | -.--% | 15.6B | |
| 16.58x | 4.78x | 11.21x | -.--% | 13.18B | |
| -421.16x | 28.6x | -3188.16x | -.--% | 12.01B | |
| 39.27x | 15.14x | 44.47x | -.--% | 11.87B | |
| Average | -33.55x | 10.92x | -312.06x | 0.21% | 21.31B | |
| Weighted average by Cap. | -11.11x | 8.33x | -170.01x | 0.39% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- IVACC Stock
- Valuation Intervacc AB
Select your edition
All financial news and data tailored to specific country editions
